We choose products where there is clear differentiation and an unmet clinical need.
As an independent, privately-held and profitable business, we can make decisions quickly. We have the resources and capabilities to explore innovative solutions to meet the needs of patients, prescribers, payers and partners alike. We offer a focused and committed approach and our abilities have been demonstrated through multiple product launches with various partners, in differing regulatory environments.Thanks to a strong balance sheet and a commercial focus, our business is able to invest in long-term collaborations and partnerships to expand our portfolio of products and to support our partners’ needs.
Our team has extensive experience working across a broad range of therapeutic areas.
Our current portfolio includes a wide range of products in three main therapeutic areas: women’s health, urology and endocrinology.
Contraception is a choice and Consilient Health is proud to offer a range of contraceptive care products to allow women a choice of method in partnership with their healthcare professional. We have a range of oral contraceptive pills in a number of our countries and that range has been designed to meet the differing needs of patients. With our patient-centric focus we were able to identify and implement an innovative approach in the complex contraceptive care market.
Other methods are available and that includes long acting reversible contraceptives (LARCs) and also non-hormonal methods for women who either cannot, or do not wish to, take hormones. We are actively looking to expand our portfolio and make more choice available to patients.
The UK was our first country for women’s health – read more about our current partnerships and success in the market here.
Find out more information about our products for women’s health.
The menopause is a natural part of ageing that usually occurs between 45 and 55 years of age. It can occur earlier, sometimes related to gynaecological surgery or cancer treatment for example.
Women may suffer from one or more of a range of symptoms including hot flushes, night sweats, vaginal dryness and discomfort during sex, reduced sex drive (libido), difficulty sleeping, low mood, anxiety and problems with memory or concentration. Some women have no symptoms or only very mild ones.
Other women have symptoms that trouble them and visiting a doctor to discuss options is recommended. Consilient Health offers a range of hormone replacement therapy (HRT treatments) that are designed to suit different women.
To discuss partnering opportunities in women's healthContact us
Bladder Pain Syndrome (BPS) or Interstitial Cystitis
Bladder pain syndrome (BPS) is also known as interstitial cystitis. BPS is an uncommon but debilitating condition, most commonly presenting in women, generally in their 40’s.
In Europe, treatment options have been limited to unlicensed medicines that are non-specific e.g. analgesia and tricyclic antidepressants. There are also medical devices such as bladder instillations that can be painful for the patient and require hospital admission and its associated costs.
Consilient Health are proud to offer patients a treatment option for this painful condition.
Overactive Bladder Syndrome
Overactive bladder syndrome (OAB) is a common condition that can affect patients’ lives significantly. Patients typically suffer from urgency and frequency of urination as well as nocturia (needing to urinate at night). Sometimes urge incontinence (leaking when they feel the urge to urinate) is a feature.
Some people may feel embarrassed to talk to their doctor, however there are a range of effective treatments and Consilient Health are pleased to offer options for these patients.
To discuss partnering opportunities in urologyContact us
Growth Hormone Deficiency
Growth hormone deficiency (GHD) can either be genetic or as a result of trauma or disease later in life
GHD occurs when the pituitary gland does not produce enough growth hormone and it occurs, for genetic reasons, in around 1 in 7,000 births. It is one potential reason why a child is not meeting height and weight growth standards for their age and it can also cause them have to have younger, rounder faces and perhaps carry some “baby fat”.
In some patients, GHD is something they develop later when it is known as acquired GHD. This may occur due to serious head injury, a pituitary tumour or radiation therapy for example.
If GHD happens in a child, puberty may be delayed or sexual development is halted. In adults symptoms include more frequent fractures, weight gain, increased blood cholesterol, feeling tired or lacking stamina and psychological symptoms like depression, anxiety, lack of concentration or poor memory.
After underlying issues are managed, GHD and its symptoms can be treated with synthetic growth hormone and to do that an accurate diagnosis is needed. Consilient Health are able to offer options for the diagnosis of this treatable condition.
Find our more about our products for GHD
Our Bone Health portfolio includes a growing number of vitamin D3 (colecalciferol) prescription medicines.
Some of them are plain, some combination, as well as bisphosphonates which are a standard treatment for osteoporosis.
We recognised that the bone health market has unmet needs with a lack of dose and formulation choices for healthcare professionals and their patients. We are proud to offer a broad range of medicines which gives patients and healthcare professionals a choice of options to suit their medical needs and personal preferences.
Find out more information about our range of products for bone health.
Diseases of Cortisol Deficiency
Diseases of Cortisol Deficiency are rare in children.
They can occur when the adrenal glands do not produce adequate amounts of steroid hormones, primarily cortisol, but there are also other causes.
Treatment options for children in Europe have mainly used adult formulations of medicines which may not be very easy for children to take, or parents and carers to manage.
Consilient Health are proud to be able to offer young patients a treatment option for this potentially life-threatening condition.
Diabetes and Obesity
Globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980.2 Over the same period obesity has more than doubled in incidence globally.1
We have a slow release treatment for type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.
One of our new therapies helps patients with obesity lose weight. Its mode of action offers an alternative to existing therapies currently on the market.
Find out more information about our products to treat diabetes and our obesity medicines.
1 World Health Organization 2016
2 Global report on diabetes, World Health Organisation, 7 April 2016.
To discuss partnering opportunities in endocrinologyContact us
We work with a broad range of pharmaceutical companies to develop and licence generic products for the UK market.
Find out more information about our generics offering in the UK.
To discuss partnering opportunities in genericsContact us